The abstract is read at the publisher; the summary is JClub's.
Chemotherapy in 152 premenopausal women with breast cancer reduces ovarian reserve, with the largest AMH declines at 6 months in women undergoing OTC and aged ≥35 years.
- Why it matters: Large prospective data are limited on how chemotherapy affects ovarian reserve measured by both AMH and AFC, and whether the impact differs by fertility preservation strategy and age.
- What they did: In a combined retro/prospective cohort at Rigshospitalet (2018–2023), ovarian reserve was assessed by AMH and AFC at baseline and 6, 12, and 24 months after chemotherapy, analyzed with linear mixed models adjusted for baseline age and hormonal contraceptive use.
- The result: Adjusted median AMH fell by 90% at 6 months and 75% at 24 months without OTC, versus 93% at 6 months and 85% at 24 months with OTC; similar but less pronounced patterns were seen for AFC, with partial recovery within 2 years.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.